Trevena, Inc. TRVN Open Trevena, Inc. in new tab
Trevena, Inc. Analysis (TRVN)
Is Trevena, Inc. a good investment? Trevena, Inc. (TRVN) is currently trading at 0.0110 USD.
Earnings Schedule: Trevena, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -19.85.
Investor FAQ
Does Trevena, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Trevena, Inc.?
Trevena, Inc. is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -48.89.
Company Profile
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Community Discussion